ArticleCytotechnology2025
KPNA2 promotes lung adenocarcinoma progression by inducing glycolysis-assisted MYC nuclear translocation.
Article in Cytotechnology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study aims to validate the biological markers of lung adenocarcinoma (LUAD) to increase early diagnosis and improve patient survival. Initially, the data of KPNA2 expression in LUAD was extracted from databases such as CCLE, TCGA, GTEx, and GEO, among others. The LUAD cells were transfected with lentivirus carrying KPNA2 cDNA or shRNA and screened with puromycin to construct the KPNA2 overexpression or knockdown stable cell lines. Further, the effect of KPNA2 on the LUAD cells in vitro was determined by the EdU assay for proliferation and flow cytometric (FCM) analysis to assess apoptosis and ROS levels. An immunofluorescence assay was used to detect the expression of MYC and its distribution. The interaction between KPNA2 and MYC was examined using co-immunoprecipitation (Co-IP) assays. Finally, a nude mouse tumorigenicity assay was applied to detect the influence of KPAN2 on tumor growth in vivo. According to database analysis, KPNA2 was expressed higher in LUAD tissues than adjacent normal tissues, indicating its positive correlation with the degree of tumor malignancy. In vitro
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.